Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Inclusion Criteria:

Diagnosed asthma
Male and female patients aged >18 and <75 years
Patients who have been treated with medium or high dose ICS plus LABA with up to 2 additional controllers
Morning pre-BD FEV1 value of ≥ 40% and ≤ 85% of the predicted normal
A positive reversibility test
ACQ-5 score of ≥ 1.5 at screening and end of run-in visits.
History of at least 1 asthma exacerbations within the 12 months prior to Screening Visit that required treatment with systemic corticosteroids (tablets, suspension or injection).

Exclusion Criteria:

Patients who have a cigarette smoking history of greater than 10 pack years or current smokers.
Pregnant or nursing (lactating) women
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using specified methods of contraception during dosing of study drug and one week after last study drug treatment
Patients with a history of immunodeficiency disease or hepatitis B or hepatitis C or HIV.